NCT06389292Phase 3Recruiting

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Study sponsor: Ascentage Pharma Group Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-05-25Estimated
Enrollment · participants486Estimated
Source updated2025-11-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview